IMRX · NASDAQ · Biotechnology

Immuneering (IMRX)

Develops oral Deep Cyclic Inhibitors for MAPK-pathway-driven cancers.

$5.02
At close+0.17 (+3.61%)

Something off on this page? Send us feedback.

Next report
Nov 11, 2026
in 69 days
EPS estimate
−$0.29
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.58−$0.42−$0.40−$0.38−$0.18−$0.21−$0.27Pending
Estimate−$0.42−$0.41−$0.40−$0.37−$0.31−$0.30−$0.26−$0.29
Surprise−38.1%−2.4%0.0%−2.7%+41.9%+30.0%−2.2%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$361.0KPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.29
Aug 2026−$0.26−$0.27−2.2%
May 2026−$0.30−$0.21+30.0%
Mar 2026−$0.31−$0.18+41.9%
Nov 2025−$0.37−$0.38−2.7%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Sep 2021
Jul 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 11, 2026−$0.29
Aug 5, 2026−$0.26−$0.27−2.2%$361.0K−0.2%
May 15, 2026−$0.30−$0.21+30.0%−5.6%
Mar 6, 2026−$0.31−$0.18+41.9%+5.4%
Nov 12, 2025−$0.37−$0.38−2.7%−2.6%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 13, 2025
May 5, 2025
Mar 20, 2025
Nov 13, 2024
Aug 6, 2024
May 7, 2024
Mar 1, 2024
Nov 9, 2023
Aug 3, 2023
May 4, 2023
Mar 6, 2023
Nov 10, 2022
Aug 10, 2022
May 10, 2022
Mar 10, 2022
Nov 9, 2021
Sep 9, 2021
Jul 30, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020